SABCS 2024 Insights: Impact of Oncotype DX Risk Stratification on Chemotherapy Use and Survival Outcomes in HR Node- eBC

Economic Impact of Oncotype DX on Breast Cancer Management

PUT CHEMO TO THE TEST. Oncotype DX® is the only test that knows if chemo is needed for early-stage breast cancer. | Until Everyone Knows

Dr. Tripathy on the Oncotype DX Assay Recurrence Score | OncLive

Dr. Febbo Explains the Oncotype DX Genomic Prostate Score | OncLive

The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows

Oncotype DX Used for Patients With Breast Cancer to Guide Therapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Test Oncotype DX Breast Recurrence Score®: test genomowy dla kobiet z rakiem piersi